119 related articles for article (PubMed ID: 16788001)
1. Baseline MRI delivery characteristics predict change in invasive ductal breast carcinoma PET metabolism as a result of primary chemotherapy administration.
Semple SI; Staff RT; Heys SD; Redpath TW; Welch AE; Ahearn TS; Hutcheon A; Gilbert FJ
Ann Oncol; 2006 Sep; 17(9):1393-8. PubMed ID: 16788001
[TBL] [Abstract][Full Text] [Related]
2. Association between serial dynamic contrast-enhanced MRI and dynamic 18F-FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer.
Partridge SC; Vanantwerp RK; Doot RK; Chai X; Kurland BF; Eby PR; Specht JM; Dunnwald LK; Schubert EK; Lehman CD; Mankoff DA
J Magn Reson Imaging; 2010 Nov; 32(5):1124-31. PubMed ID: 21031518
[TBL] [Abstract][Full Text] [Related]
3. Can FDG-PET/CT predict early response to neoadjuvant chemotherapy in breast cancer?
Andrade WP; Lima EN; Osório CA; do Socorro Maciel M; Baiocchi G; Bitencourt AG; Fanelli MF; Damascena AS; Soares FA
Eur J Surg Oncol; 2013 Dec; 39(12):1358-63. PubMed ID: 24120422
[TBL] [Abstract][Full Text] [Related]
4. Glycolytic activity with 18F-FDG PET/CT predicts final neoadjuvant chemotherapy response in breast cancer.
García Vicente AM; Cruz Mora MÁ; León Martín AA; Muñoz Sánchez Mdel M; Relea Calatayud F; Van Gómez López O; Espinosa Aunión R; Gonzalez Ageitos A; Soriano Castrejón A
Tumour Biol; 2014 Nov; 35(11):11613-20. PubMed ID: 25139100
[TBL] [Abstract][Full Text] [Related]
5. Multimodal prediction of neoadjuvant treatment outcome by serial FDG PET and MRI in women with locally advanced breast cancer.
Kazerouni AS; Peterson LM; Jenkins I; Novakova-Jiresova A; Linden HM; Gralow JR; Hockenbery DM; Mankoff DA; Porter PL; Partridge SC; Specht JM
Breast Cancer Res; 2023 Nov; 25(1):138. PubMed ID: 37946201
[TBL] [Abstract][Full Text] [Related]
6. Monitoring of neoadjuvant chemotherapy using multiparametric, ²³Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer.
Jacobs MA; Ouwerkerk R; Wolff AC; Gabrielson E; Warzecha H; Jeter S; Bluemke DA; Wahl R; Stearns V
Breast Cancer Res Treat; 2011 Jul; 128(1):119-26. PubMed ID: 21455671
[TBL] [Abstract][Full Text] [Related]
7. Correlation Between F-18 Fluorodeoxyglucose Positron Emission Tomography Metabolic Parameters and Dynamic Contrast-Enhanced MRI-Derived Perfusion Data in Patients with Invasive Ductal Breast Carcinoma.
Kim TH; Yoon JK; Kang DK; Lee SJ; Jung YS; Yim H; An YS
Ann Surg Oncol; 2015 Nov; 22(12):3866-72. PubMed ID: 25805237
[TBL] [Abstract][Full Text] [Related]
8. The relationship between vascular and metabolic characteristics of primary breast tumours.
Semple SI; Gilbert FJ; Redpath TW; Staff RT; Ahearn TS; Welch AE; Heys SD; Hutcheon AW; Smyth EH; Chaturvedi S
Eur Radiol; 2004 Nov; 14(11):2038-45. PubMed ID: 15316743
[TBL] [Abstract][Full Text] [Related]
9. The assessment of breast cancer response to neoadjuvant chemotherapy: comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography.
Park JS; Moon WK; Lyou CY; Cho N; Kang KW; Chung JK
Acta Radiol; 2011 Feb; 52(1):21-8. PubMed ID: 21498321
[TBL] [Abstract][Full Text] [Related]
10. PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake.
Dunnwald LK; Doot RK; Specht JM; Gralow JR; Ellis GK; Livingston RB; Linden HM; Gadi VK; Kurland BF; Schubert EK; Muzi M; Mankoff DA
Clin Cancer Res; 2011 Apr; 17(8):2400-9. PubMed ID: 21364034
[TBL] [Abstract][Full Text] [Related]
11. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
Coudert B; Pierga JY; Mouret-Reynier MA; Kerrou K; Ferrero JM; Petit T; Kerbrat P; Dupré PF; Bachelot T; Gabelle P; Giard S; Coeffic D; Bougnoux P; Prevost JB; Paintaud G; Thibault G; Hernandez J; Coudert M; Arnould L; Berriolo-Riedinger A
Lancet Oncol; 2014 Dec; 15(13):1493-1502. PubMed ID: 25456368
[TBL] [Abstract][Full Text] [Related]
12. Dynamic 2-Deoxy-2-[
Kristian A; Holtedahl JE; Torheim T; Futsaether C; Hernes E; Engebraaten O; Mælandsmo GM; Malinen E
Mol Imaging Biol; 2017 Apr; 19(2):271-279. PubMed ID: 27541026
[TBL] [Abstract][Full Text] [Related]
13. The role of chemotherapeutic drugs in the evaluation of breast tumour response to chemotherapy using serial FDG-PET.
Schneider-Kolsky ME; Hart S; Fox J; Midolo P; Stuckey J; Hofman M; Ganju V
Breast Cancer Res; 2010; 12(3):R37. PubMed ID: 20565953
[TBL] [Abstract][Full Text] [Related]
14. The Prognostic Impact of Early Change in 18F-FDG PET SUV After Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer.
Lee HW; Lee HM; Choi SE; Yoo H; Ahn SG; Lee MK; Jeong J; Jung WH
J Nucl Med; 2016 Aug; 57(8):1183-8. PubMed ID: 27033896
[TBL] [Abstract][Full Text] [Related]
15. Reliability of
Jena A; Taneja S; Singh A; Negi P; Sarin R; Das PK; Singhal M
AJR Am J Roentgenol; 2017 Sep; 209(3):662-670. PubMed ID: 28678576
[TBL] [Abstract][Full Text] [Related]
16. [Value of fused 18F-FDG PET/CT images in predicting efficacy of neoadjuvant chemotherapy on breast cancer].
Li D; Chen JH; Wang J; Ling R; Yao Q; Wang L
Ai Zheng; 2007 Aug; 26(8):900-4. PubMed ID: 17697556
[TBL] [Abstract][Full Text] [Related]
17. Response to neoadjuvant treatment of invasive ductal breast carcinomas including outcome evaluation: MRI analysis by an automatic CAD system in comparison to visual evaluation.
Böttcher J; Renz DM; Zahm DM; Pfeil A; Fallenberg EM; Streitparth F; Maurer MH; Hamm B; Engelken FJ
Acta Oncol; 2014 Jun; 53(6):759-68. PubMed ID: 24299492
[TBL] [Abstract][Full Text] [Related]
18. Serial integrated (18)F-fluorodeoxythymidine PET/CT monitoring neoadjuvant chemotherapeutic response in invasive ductal carcinoma.
Beresford M; Lyburn I; Sanghera B; Makris A; Wong WL
Breast J; 2007; 13(4):424-5. PubMed ID: 17593051
[No Abstract] [Full Text] [Related]
19. 18F-FDG semi-quantitative parameters and biological prognostic factors in locally advanced breast cancer.
García Vicente AM; Soriano Castrejón A; Relea Calatayud F; Muñoz Madero V; Molina Garrido MJ; León Martín AA; Cordero García JM; Pilkington Woll JP; Chacón López-Muñiz I; Palomar Muñoz A
Rev Esp Med Nucl Imagen Mol; 2012; 31(6):308-14. PubMed ID: 23084013
[TBL] [Abstract][Full Text] [Related]
20. 18 F-fluorodeoxyglucose uptake predicts pathological complete response after neoadjuvant chemotherapy for breast cancer: a retrospective cohort study.
Jin S; Kim SB; Ahn JH; Jung KH; Ahn SH; Son BH; Lee JW; Gong G; Kim HO; Moon DH
J Surg Oncol; 2013 Feb; 107(2):180-7. PubMed ID: 22948739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
